Gilead Sciences Q4 Earnings Preview

Gilead Sciences (GILD) Q4 2024 Earnings Call Transcript
Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared remarks,
Gilead Sciences Shares Push Higher After Q4 Report: Here's Why
Gilead Sciences reported its fourth-quarter financial results after Tuesday's closing bell. Here's a look at the highlights from the report:
Gilead: Q4 Earnings Snapshot
Gilead Sciences Inc. (GILD) on Tuesday reported fourth-quarter earnings of $1.78 billion. The Foster City, California-based company said it
Gilead Sciences Beats Q4 EPS Forecast
Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.
Gilead (GILD) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Gilead Sciences (GILD) reported $7.57 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 6.4%. EPS of $1.90 for the same period compares to $1.72 a year ago.
Gilead Sciences (NASDAQ:GILD) Delivers Strong Q4 Numbers
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) reported in Q4 CY2024, with sales up 6.4% year on year to $7.57 billion. The company expects the full year’s revenue to be around $28.4 billion,
Gilead Sciences Q4 Earnings Preview: Slight fall in profit expected
Gilead Sciences (NASDAQ:GILD) is scheduled to announce Q4 earnings results on Tuesday, February 11th, after market close. Analysts expect a profit of $1.70 per share (-1.2% Y/Y) on revenue of $7.15B (+0.
Gilead provides upbeat 2025 forecast, shares rise 4%
Gilead Sciences posted fourth-quarter results that exceeded Wall Street expectations and forecast 2025 earnings above analyst ...
Gilead Sciences: Diversification Strategy Not Derisked Enough Yet
Gilead Sciences faces revenue growth challenges as its blockbuster drugs lose exclusivity by 2033. Check out my ...
Gilead Sciences 4Q Profit Up on HIV Product Sales, Dividend Raised
Gilead Sciences' earnings beat Wall Street expectations driven by a boost in HIV product sales. The biopharmaceutical company posted a fourth quarter profit of $1.78 billion, or $1.42 a share, ...
Gilead quarterly results beat estimates
Gilead Sciences posted fourth-quarter results that exceeded Wall Street estimates on Tuesday as its HIV drug sales rose 16% ...
Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Gilead (GILD), consensus $1.70… DoorDash (DASH), ...
Gilead Sciences Inc. stock outperforms competitors on strong trading day
Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...
Top Analyst Reports for Uber, Comcast & Gilead
Today's Research Daily features new research reports on 16 major stocks, including Uber Technologies, Inc. (UBER), Comcast ...
Gilead Sciences, Inc. (GILD) Q4 2024 Earnings Call Transcript
Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...
Gilead Beats Earnings Estimates on Strong HIV Sales. The Stock Is Rising.
Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.